International Organising Committee
Meir Bialer (Israel) Co-Chair
Meir Bialer is the David H. Eisenberg Professor of Pharmacy at the School of Pharmacy, Faculty of Medicine of The Hebrew University of Jerusalem. He received his B.Pharm, M.Sc., M.B.A. and Ph.D. degrees from The Hebrew University of Jerusalem. Dr. Bialer completed a postdoctoral fellowship in pharmacokinetics at the University of Florida and spent an additional year at the College of Pharmacy at the University of Kentucky. Since 1980 he has been a member of the faculty of the School of Pharmacy of The Hebrew University of Jerusalem and from 1994-1997 served as the Head of the Department of Pharmaceutics in the School of Pharmacy. Professor Bialer is a Fellow (1992) of the American Association of Pharmaceutical Scientists (AAPS) an Ambassador for Epilepsy (2001), an award of The International League Against Epilepsy ( ILAE) and The International Bureau for Epilepsy (IBE). He is also am Expert member of the Board of Pharmaceutical sciences (BPS) of the FIP (Federation Intenationale Pharmaceutique). He ser ves as a member of the editorial board of the following international journals:, Bipharmaceutics & Drug Disposition,:(1988-present), CNS Drugs (1994-present),: Epilepsia (2000-present),: Epilepsy & Behavior (2003-present),: European Journal of Pharmaceutical Sciences (1992-1998),: Journal of Pharmaceutical Sciences (1990-1995), and Therapeutic Drug Monitoring (1999-present).
Dr. Bialer’s research interests include: a: Pharmacokinetics of new antiepileptics and CNS drugs and their drug interactions. b: Pharmacokinetic-based design of new antiepileptics and CNS drugs with better potency, lack of teratogenicity and a wide safety margin. In this regard he has been utilizing structure pharmacokinetic pharmacodynamic relationship (SPPR) studies to develop novel valproyl, phthaloyl and cyclopropyl derivatives of glycine and GABA as new AEDs. c: Stereospecific pharmacokinetics and pharmacodynamics d) Phrmacogenetics of drugs and the correlation between genotyping and phemotyping. In these areas he has published 165 publications in peered review journals.
Dr. Bialer’s research interests include: a: Pharmacokinetics of new antiepileptics and CNS drugs and their drug interactions. b: Pharmacokinetic-based design of new antiepileptics and CNS drugs with better potency, lack of teratogenicity and a wide safety margin. In this regard he has been utilizing structure pharmacokinetic pharmacodynamic relationship (SPPR) studies to develop novel valproyl, phthaloyl and cyclopropyl derivatives of glycine and GABA as new AEDs. c: Stereospecific pharmacokinetics and pharmacodynamics d) Phrmacogenetics of drugs and the correlation between genotyping and phemotyping. In these areas he has published 165 publications in peered review journals.
